Dr. Reddy's Q3 FY26: Navigating Headwinds with Strategic Growth

Dr. Reddy's Laboratories Ltd. (DRREDDY) has announced its consolidated financial results for the third quarter of fiscal year 2026, ending December 31, 2025. The pharmaceutical giant reported revenues of ₹8,727 crore, marking a 4.4% year-on-year growth, though experiencing a slight sequential decline of 0.9%. Despite facing headwinds from lower Lenalidomide sales and continued pricing pressure, the company demonstrated resilient performance, largely driven by double-digit growth in its underlying base businesses and favorable foreign exchange movements. Profit after tax stood at ₹1,210 crore, a 14% decrease year-on-year, while EBITDA was ₹2,049 crore. Excluding a one-time provision related to new Labour Codes in India, the underlying EBITDA margin was a healthy 24.8%, underscoring steady profitability.

Segmental Performance and Growth Drivers

The company's performance was a tale of two halves, with strong growth in branded businesses offsetting challenges in generics. The Global Generics segment contributed ₹7,911.3 crore, accounting for 90.7% of total revenue. This segment saw robust growth in India and Emerging Markets. India's business reported a healthy 19% year-on-year growth to ₹1,603 crore, driven by an innovation portfolio, new brand launches, price increases, and higher volumes, including contributions from the recently acquired Stugeron portfolio. The company continues to outperform the Indian Pharmaceutical Market (IPM), with a moving quarterly total (MQT) growth of 12.3% against IPM's 11.8%.

Emerging Markets delivered a strong performance, with revenues of ₹1,896 crore, reflecting a 32% year-on-year growth and 15% sequentially. This growth was primarily fueled by new product launches across various markets and favorable forex. Russia, a key market within this segment, grew by 51% year-on-year to ₹1,060 crore. In contrast, North America generics experienced a decline of 12% year-on-year to ₹2,964 crore, primarily due to lower Lenalidomide sales and continued pricing pressure. The Pharmaceutical Services and Active Ingredients (PSAI) segment reported revenues of ₹801.8 crore, a 2% decline year-on-year and a 15% sequential drop, mainly due to lower volume uptake in the API business.

Strategic Initiatives and Pipeline Progress

Dr. Reddy's continued to advance its strategic priorities, focusing on base business growth, pipeline advancement, and operational efficiencies. A significant highlight was the strategic collaboration with Immutep for the commercialization of Eftilagimod Alfa, a novel immunotherapy oncology drug, in key Emerging Markets. The company launched Hevaxin®, a recombinant vaccine for Hepatitis-E virus infection, in India. Integration of 85% of the acquired Nicotine Replacement Therapy (NRT) business by value was completed by December 2025, with full integration expected by the fiscal year-end.

On the regulatory front, Dr. Reddy's received Marketing Authorisation for Semaglutide injection in India and is awaiting Canadian approval, expected between February and May 2026. The Biologics License Application (BLA) for abatacept biosimilar (IV) was filed in the US in December 2025, with approval anticipated by late 2026. While the denosumab biosimilar received European Commission and MHRA, UK approval and was launched in Germany, a Complete Response Letter from the USFDA was issued due to observations at their partner Alvotech's manufacturing facility. Similarly, a CRL for rituximab biosimilar BLA was received in relation to ongoing observations at the Bachupally biologics facility.

Financial Health and Outlook

The company's financial health remains strong, with a net cash surplus of ₹3,069 crore as of December 31, 2025. Capital expenditure for the quarter stood at ₹669 crore, and free cash flow generated was ₹374 crore. Management indicated that the India business growth is sustainable in the 15-18% range, and the underlying EBITDA margin is expected to remain around 25%. Gross margins for Global Generics and PSAI are projected to be in the 50-55% range from Q4 onwards, excluding Lenalidomide sales. The company also announced Science-Based Net Zero Climate Targets by FY2045, showcasing its commitment to sustainability and leadership in environmental stewardship.

Conclusion: Disciplined Execution Amidst Evolving Markets

Dr. Reddy's Q3 FY26 results reflect a period of disciplined execution and strategic focus. Despite specific product headwinds, particularly in North America, the company's diversified business model and strong performance in branded markets and new product launches have ensured overall steady profitability. The ongoing integration of the NRT business, advancements in the biosimilar pipeline, and a strong commitment to sustainability position Dr. Reddy's to navigate evolving market dynamics and create long-term value for its stakeholders.